Last reviewed · How we verify

NCT06627543

Effect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3

ENROLLING BY INVITATION Last updated 4 October 2024
What this trial tests

trial testing echo in Gaucher Disease Type 3 in 44 participants. Enrolling by invitation.

Timeline
1 April 2024
Primary endpoint
1 January 2025
1 March 2025

Quick facts

Lead sponsorNoha Osman
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment44
Start date1 April 2024
Primary completion1 January 2025
Estimated completion1 March 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Noha Osman

Who can join

Eligibility, any sex, with Gaucher Disease Type 3. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

all cases confirmed diagnosis of Gaucher disease type 3 recieving enzyme replacement therapy at Assiut university hospital

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gaucher Disease Type 3

Currently open trials in the same condition.

Other Noha Osman trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06627543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing